Acurx Pharmaceuticals Inc. (ACXP) carries a Roarable Rating of E (Strong Sell) with 33/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Acurx Pharmaceuticals Inc. (NASDAQ: ACXP) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $1.04 (-2.80% 1D, market cap $5.8M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ACXP ranks #703 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ACXP carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ALZN (Alzamend Neuro Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $5.8M) and SKYE (Skye Bioscience Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $5.7M). Among the 5-stock peer group, ACXP leads on earnings multiple (N/A) while ACXP leads on capital efficiency (-35.0% ROIC).
Per ACXP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001736243), Acurx Pharmaceuticals Inc. generated $0 in revenue, -$8.0M in net income, and -$6.8M in free cash flow against $7.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 30.2 (OVERSOLD (<32))
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
While ACXP currently carries a cautious 33/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.28) and Max Pain ($1.09) forces dealer call-delta covering toward $7.92.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Acurx Pharmaceuticals Inc. (ACXP) dropped -2.80% to $1.04, trading at 2% of its 52-week range ($1.03 – $7.54). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo! Finance Canada report covering Acurx Pharmaceuticals Inc. (ACXP) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Acurx Pharmaceuticals Inc. (ACXP) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Acurx Pharmaceuticals Inc. (ACXP) market action, institutional positioning, and fundamental catalysts.
Investing.com South Africa report covering Acurx Pharmaceuticals Inc. (ACXP) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering Acurx Pharmaceuticals Inc. (ACXP) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering Acurx Pharmaceuticals Inc. (ACXP) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering Acurx Pharmaceuticals Inc. (ACXP) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering Acurx Pharmaceuticals Inc. (ACXP) market action, institutional positioning, and fundamental catalysts.
Stewards Investment Capital, FreeCast (NASDAQ:CAST) and BioVie (NASDAQ:BIVI) Headline a Four-Region Broadcast Across the U., Latin America, MENA and Southeast AsiaNEW YORK CITY, NY / ACCESS Newswire / October 31, 2026 /
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for serious and life threatening bacterial infections, announced today t
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ACXP today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ACXP. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Acurx Pharmaceuticals Inc. (ACXP) ranks #703 by composite RQD confidence (33/100, grade E) and #930 by equity capitalization ($5.8M). Within this direct 5-issuer industry benchmark cohort, ACXP leads on earnings valuation at N/A trailing P/E, while ACXP leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. APRE currently holds the highest overall quantitative score in the immediate peer group at 40/100 (D-) compared with ACXP at 33/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ACXP
ACTIVE
Acurx Pharmaceuticals Inc. | E | 33/100 | — | — | -35.0% | -2.80% | $5.8M | Benchmark Subject |
| ALZN Alzamend Neuro Inc. | E | 34/100 | — | — | -35.0% | -0.82% | $5.8M | /alzn-vs-acxp → |
| SKYE Skye Bioscience Inc. | E | 34/100 | — | — | -35.0% | -2.29% | $5.7M | /skye-vs-acxp → |
| BGMS Bio Green Med Solution Inc. | D- | 38/100 | — | — | -35.0% | +8.43% | $6.0M | /bgms-vs-acxp → |
| APRE Aprea Therapeutics Inc. | D- | 40/100 | — | — | -35.0% | -1.82% | $6.1M | /apre-vs-acxp → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Acurx Pharmaceuticals Inc. (ACXP) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$8.0M, operating cash flow of -$6.8M, and free cash flow of -$6.8M (+34.6% YoY). On the balance sheet, ACXP closed FY2025 with $7.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$8.0M | -$6.8M | -$6.8M | $7.7M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$14.1M | -$10.4M | -$10.4M | $3.9M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$14.6M | -$9.8M | -$9.8M | — | — |
As of 2026-11-03, Acurx Pharmaceuticals Inc. (NASDAQ: ACXP) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $1.04 (-2.80% 1D, market cap $5.8M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ACXP ranks #703 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ACXP carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ALZN (Alzamend Neuro Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $5.8M) and SKYE (Skye Bioscience Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $5.7M). Among the 5-stock peer group, ACXP leads on earnings multiple (N/A) while ACXP leads on capital efficiency (-35.0% ROIC).
Per ACXP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001736243), Acurx Pharmaceuticals Inc. generated $0 in revenue, -$8.0M in net income, and -$6.8M in free cash flow against $7.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
ACXP last traded at $1.04 (-2.80% on volume of 63,198 shares), positioning the stock -18.75% below its 50-day simple moving average ($1.28) and -46.94% below its 200-day simple moving average ($1.96). Across its 52-week range of $1.03 to $7.54, ACXP sits at the 0.2% percentile with a 14-day RSI of 30.2 (OVERSOLD (<32)) and an implied next-earnings move of ±9.6% ($1.00 to $1.14).
Why ACXP Stock dropped -2.80% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, ACXP scores 33 out of 100, grade E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are: Fundamental Cash Engine 6/20 (ROIC -35%; FCF yield 0%); Whale 13F Flow 3/20 (institutional accumulation and options positioning); Insider Conviction 5/20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit 9/20 (Beta 1.0; sector sensitivity); and Forensic Balance Sheet 10/20 (Altman Z 2.5; Piotroski F 2/9; Debt/Equity 0.5).
For a prospective investor, the weakest pillars are the cash engine and institutional/insider signals. A -35% ROIC and 0% FCF yield indicate the business is not currently generating returns on capital or free cash flow, so any valuation rests on future outcomes rather than present cash generation. The Piotroski F-Score of 2/9 signals weak fundamental health across the nine checks, while the Altman Z of 2.5 and Debt/Equity of 0.5 are the relatively steadier elements of the forensic picture. The low whale and insider scores mean the source data shows little evidence of conviction from large holders or insiders to offset these concerns. Upside would depend on a catalyst that changes the cash-generation picture; the data contains no such evidence, so the rating reflects present forensic risk rather than a forecast.
Acurx Pharmaceuticals Inc. is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Per the company profile, its market capitalization is $0.0B on a rounded basis, with the market data showing $5.9M. The source data does not describe specific products, customers, or revenue model. Reported revenue is $0.0M across the periods provided, indicating no revenue recognition in those years.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.0M | $-8.1M | $-8.0M | N/A | $-6.8M | N/A | N/A |
| FY 2024 | $0.0M | $-14.1M | $-14.1M | N/A | $-10.4M | N/A | N/A |
| FY 2023 | $0.0M | $0.0M | $-14.6M | N/A | $-9.8M | N/A | N/A |
Per the SEC financials, net losses narrowed from $-14.6M (FY 2023) to $-14.1M (FY 2024) to $-8.0M (FY 2025), and free cash flow moved from $-9.8M to $-10.4M to $-6.8M over the same span. Gross, operating, and net margins are reported as 0% in the market data, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9, with Debt/Equity at 0.5. Cash and debt balances are not available in source data.
Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE, with no butterfly links and no proprietary signals. The source data therefore does not identify upstream suppliers, downstream customers, or sector correlations beyond the stated Health Care sector and Biotechnology: Pharmaceutical Preparations industry classification. The one second-order consideration the data supports is that a pre-revenue profile with negative cash flow implies dependence on external funding, but the source data does not specify financing sources or terms. Watch for the Nov. 12 results release as the next data point on the loss trajectory.
Real-time company headlines, analyst actions, and sector developments for Acurx Pharmaceuticals Inc. (ACXP) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo! Finance Canada report covering Acurx Pharmaceuticals Inc. (ACXP) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Acurx Pharmaceuticals Inc. (ACXP) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Acurx Pharmaceuticals Inc. (ACXP) market action, institutional positioning, and fundamental catalysts.
Investing.com South Africa report covering Acurx Pharmaceuticals Inc. (ACXP) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering Acurx Pharmaceuticals Inc. (ACXP) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering Acurx Pharmaceuticals Inc. (ACXP) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering Acurx Pharmaceuticals Inc. (ACXP) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering Acurx Pharmaceuticals Inc. (ACXP) market action, institutional positioning, and fundamental catalysts.
Welcome to the ACXP (Acurx Pharmaceuticals Inc.) Roar Pit. Current RQD Composite is 33/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on ACXP, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Acurx Pharmaceuticals Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on ACXP, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $1.07 (52-wk range $1.03 - $7.54), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).